Boosting lubricin to protect knees after ACL and other knee injuries
Small molecule stimulation of lubricin for treatment of post-traumatic osteoarthritis
Researchers are trying to find FDA-approved drugs that raise lubricin, a natural joint lubricant, to help people with knee injuries like ACL tears avoid post-traumatic osteoarthritis.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Central Florida NIH-funded |
| Lab location | 1 site (Orlando, United States) |
| Project ID | NIH-11170609 on NIH RePORTER |
What this research studies
This project uses human cartilage cells that were engineered to signal when they produce lubricin, and researchers will screen approved drugs in a 3D cartilage model that mimics injured joints. Compounds that increase lubricin in the lab model will be studied further in cell tests and then in mice given a non‑invasive ACL tear to see if joint damage is reduced. The work is primarily laboratory and animal research now, intended to identify drug candidates that could later move toward human testing.
Who could benefit from this research
Good fit: People who have had a recent ACL tear or other significant knee injury and are at risk for developing post‑traumatic osteoarthritis would be the likely future candidates.
Not a fit: Patients with long-standing, severe osteoarthritis or joint damage unrelated to injury are unlikely to benefit from these early-stage approaches.
Why it matters
Potential benefit: If successful, this could lead to medicines that boost joint lubrication and slow or prevent arthritis after knee injuries.
How similar studies have performed: Delivering lubricin by gene therapy prevented osteoarthritis in mice, but pharmacologically stimulating lubricin with approved drugs in people is a newer and largely untested strategy.
Where this research is happening
Orlando, United States
- University of Central Florida — Orlando, United States (Active)
Researchers
- Principal investigator: Kean, Thomas J. — University of Central Florida
- Study coordinator: Kean, Thomas J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.